张明真老师

张明真，男，特聘研究员/博士生导师，转化医学研究院医学工

程研究所副所长。华中科技大学博士；美国佐治亚州立大学博士后、

助理教授；西安交通大学医学部基础医学院特聘研究员。主要从事

结肠炎及结肠癌的精准诊疗研究，涉及新型纳米递送系统、诊疗一

申请发明专利 6 项。主持/参与国家自然科学基金、美国 CCFA 基金会基金、科技部重点研

发计划、陕西省自然科学基金，国家卫健委胃肠肿瘤诊治重点实验室开放基金等项目 10 余

项，入选陕西省普通高校“青年杰出人才支持计划”、西安交通大学“青年拔尖人才计划”及西

安交通大学医学部“国家级后备人才支持计划”等。多次受邀作为 Advanced Functional

Materials, ACS Nano, Biomaterials 等权威杂志审稿人。现为 Frontiers inDrug Delivery 副主编，

Frontiersin MolecularBiosciences、 Catalysts 杂志客座编辑。 Frontiersin Materials, Frontiers in

BioengineeringandBiotechnology 评审编辑、 Chinese Chemical Letters 青年编委，右江医学青

年编委， Journal ofClinical andTranslational Research 编委。陕西省抗癌协会整合肿瘤免疫治

疗分会常委，陕西省纳米科技学会理事会理事，中国生物材料学会会员，中国医学工程学会会员，生物物理学会会员，中国微米纳米技术学会高级会员。

研究领域及方向 1：

以炎症性肠道疾病（IBD）和结肠癌为主要研究目标，围绕疾病诊断、治疗及致病分子

机理，开展以下工作：

file:///C:/Users/yzl05/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif 药物靶向递送。

file:///C:/Users/yzl05/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif 结肠癌声动力治疗。

file:///C:/Users/yzl05/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif 生物标记物检测与传感。

研究领域及方向 2：

碳基纳米酶性质、机理及应用开发。

申请专利：

1. 张明真，颜湘冀，杨梅，马雅娜，方碧云；一种姜黄衍生的类外泌体纳米颗粒及其制备方法；申请号： CN202010124686.0。（第一申请人）

2. Didier Merlin, Mingzhen Zhang; Compositions and methods based on plant-derived nanoparticles; 申请号： 62/438,948。（第二申请人）

3. 戴正飞，梁婷婷， 张明真，刘耀达；一种非晶硼酸钴-单硒化镍@泡沫镍的复合物、制备方法及应用；专利号： ZL2020105010005。（第三申请人）

4. 张明真，刘翠，高文慧，张保军；一种 Pt-CDs复合纳米材料以及制备方法；申请号： 202110442769.9；申请号： 202110442769.9 （第一申请人）

5. 张明真，方碧云，贾真真，张保军；一种基于个人血糖仪读数的核酸即时检测方法及其试剂盒；申请号： 2021111228613 （第一申请人）

6. 刘翠， 张明真，高文慧，庞代文，涂康生；一种具有超氧化物歧化酶活性碳点的制备方法及其催化用途；申请号： 202111289705.6 （第二申请人）

7. 张明真；韦伟；方碧云；贾真真；一种基于妊娠试纸的溶菌酶即时检测方法及其试剂盒；

学术任职：

1. 西安交通大学基础医学院青年学者委员会副主任委员

2. 右江医学杂志青年编委

3. Frontiersin Molecular Biosciences杂志客座编辑

4. 陕西省抗癌协会整合肿瘤免疫治疗分会常委

5. 陕西省纳米科技学会理事会理事

6. ChineseChemical Letters青年编委

7. Journal of Clinicaland Translational Research 编委

代表性论文：

2022年

1. Yang M,YangCH, Zhang YJ, YanXJ, Ma YN, Zhang YY,Cao YM,XuQR*, TuKS*and

Zhang MZ*. Orally pH-activated "nano-bomb" carrier combined with berberine by regulating

gene silencing and gut microbiota for site-specific treatment ofulcerative colitis. Biomaterials

Science.2022, 10(4):1053-1067. (IF=6.84)

2. Ma YN, Gao WH, Zhang YJ, Yang M, Yang XJ, Zhang YY, Li GY,Liu C*, Xu CL*and Zhang

MZ*. Biomimetic MOF nanoparticles delivery ofC-dot nanozyme and CRISPR/Cas9 system

for sitespecific treatment of ulcerative colitis. ACS Applied Materials & Interfaces. 2022,

14(5), 6358−6369. (IF=9.229)

3. Gong LY, Zhang YJ, Zhang YL, Tu KS, Jiao LY, Xu QR, Zhang MZ*and Han SX*. All-in-

one Biomimetic Nanoplatform Based on Hollow Polydopamine Nanoparticles for

SynergisticallyEnhanced Radiotherapy of Colon Cancer. Small. 2022, e2107656. (IF=13.28)

4. Yan XJ, Yang CH, Yang M,Ma YN, Zhang YY, Zhang YJ,Liu C, Xu QR*, Tu KS* and Zhang

MZ*. All-in-onetheranostic nano-platformbasedon polymer nanoparticles for BRET/FRET-

initiated bioluminescence imaging and synergisticallyanti-inflammatory therapy for ulcerative

colitis. Journal of Nanobiotechnology. 2022, 20(1): 99. (IF=10.435)

5. Liu C#,Yan XJ#, ZhangYJ#,Yang M, Ma YN, Zhang YY, XuQR*, Tu KS*and Zhang MZ*.

Turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving

bioactions for treatment of ulcerative colitis. Journal of Nanobiotechnology. 2022.

(IF=10.435)

6. Wei W, Zhang YJ, Li RQ, Cao YM, Yan XJ, Ma YN, Zhang YY, Yang M* and Zhang MZ*.

Oraldelivery of pterostilbene by L-Arginine-mediated “nano-bomb”carrierforthe treatment

ofulcerative colitis. International Journal of Nanomedicine. 2022, 17, 603-616. (IF=6.4)

7. Liu C, Wei XX, Zhang MZ, Hildebrandt N, Luo QY* and Jin ZW*. Nucleic Acid

Hybridization Enhanced Luminescence for Rapid and Sensitive RNA and DNA Based

Diagnostics (In submission).

8. Xu JW#*, Yan XJ#*, Zhang Y, Tu KS,ShenW, Tian ZQ,Zhao W*and Zhang MZ. Tunable

paclitaxel releasecarrier using diselenide-disulfide balance as regulator.Journal of Industrial

and Engineering Chemistry. 2022. (IF: 6.0644)

9. Yan XJ, Zhang XZ, Zhang YJ, Yang M, Ma YN, Zhang YY, Xu QR*, Tu KS* andZhang MZ*.

Reactive Oxygen Species-responsive Nanocarrier Ameliorates Ulcerative Colitis by

Regulating Colonic M1/M2Macrophage Polarizationand CD4+ T CellInfiltration. Journal of

Crohn's and Colitis (Under review)

10. Gao WH#, Zhang YJ#,Ma YN, Cheng LL, ZhangMX*,Liu C*, and Zhang MZ*. Pt@Carbon

Nanodotscomposite with cascade superoxide dismutasecatalase activityforversatile reactive

oxygen speciesscavenging. Angewandte Chemie. (In submission).

11. Gao WH, He JY,Chen L, MengXQ, Ma YN, Liu C*, ZhangMZ*, FanKL*, PangD-W* and

YanXY*. Deciphering the catalyticmechanism of superiorsuperoxide dismutase activityof

carbon dot nanozyme. Nature Catalysis. (In submission).

2021 年

1. Gong LY, Zhang YJ, Liu CC, Zhang MZ* and Han SX*. Applicationof Radiosensitizers in

Cancer Radiotherapy. International Journal ofNanomedicine. 2021; 16: 1083-1102. (IF=6.4)

5.

颜湘冀，张玉洁， 张明真*。中性粒细胞在溃疡性结肠炎中的作用机制及靶向治疗策略

[J]. 右江医学, 2021; 49(2): 87-91

Jia ZZ, Tu KS, Xu QR, Gao WH, Liu C, Fang BY* and Zhang MZ*. A novel disease-

associated nucleic acid sensingplatformbased on splitDNA-scaffoldedsliver nanocluster.

Analytica Chimica Acta. 2021. (IF=6.558)

WangXY#, Zhang MZ#,WoloshunR, Yu Y, Lee J,Flores S, Merlin Dand CollinsJ. Oral

Administration ofGinger-Derived Lipid Nanoparticles and Dmt1 siRNApotentiatesthe Effect

ofDietary IronRestriction andMitigatesPre-ExistingIron Overload inHampKOMice.

Nutrients. 2021,13(5), 1686. (IF=5.717)

Fang BY*, Jia ZZ, Liu C, Tu KS, Xu QR* andZhang MZ. Aversatile CRISPR Cas12a-based

point-of-care biosensorenabling convenient glucometer readout for ultrasensitive detection of

pathogen nucleicacids. (Under review)

MaYN, Qu XL, Liu C, Xu QR* and Tu KS*. Metal-organic frameworks and their composites

towards bio-medical applications. Front. Mol. Biosci. 2021, 8: 805228.

Zhou Y, Yan XJ, Yang M, Ma YN, Zhang YY, Zhang YJ, Zhang MX* and Zhang MZ*. Oral

delivery of therapeutic rographolide/carbon monoxide (CO) donor for synergistic treatment of

ulcerative colitis by anti-inflammation and pro-resolution. (In preparation)

TherapeuticAlbumin NanoparticlesHitchhike Activated Neutrophil AcrossVascularBarrier

for Subcutaneous and Orthotopic Colon Cancer Therapy (In submission)

2020 年

1. An J,Hu YG, Chang K, Li C, HouXL, WangGL, Zhang XS,Liu B, Zhao YD* and Zhang

MZ*. ROS-Augmented and Tumor-Microenvironment Responsive Biodegradable

Nanoplatform for EnhancingChemo-Sonodynamic Therapy. Biomaterials. 2020; 234: 119761.

(IF=12.479)

2. FangBY*, Guo P, Yang M, Ma YN, Yan XJ, Jia ZZ,Gao WH, Ahmad S,Xu CL, Liu C and

Zhang MZ*. A Novel Fluorescent Enhancing Platform Based on DNA-scaffolded Silver

Nanoclusters for Potential Inflammatory Bowel Disease-associatedMicroRNA Detection.

Talanta. 2020; 218: 121122. (IF=6.057)

3. Yang CH, Zhang MZ, Lama S, Wang LX and Merlin D. Natural-lipid nanoparticle-based

therapeuticapproach to deliver6-shogaol and its metabolites M2 and M13 to thecolon to treat

ulcerative colitis. Journal of Controlled Release. 2020; 323: 293-310. (IF=9.776)

4. Yang CH, Zhang MZ, Sung J, Wang LX, Jung Y and MerlinD. Isolation and Characterization

ofExosomes from MouseFeces. Bio-protocol.2020; 10(8): e3584.

5. Shi Q, Cheng YH, Dong XM, Zhang M, Pei C and Zhang MZ*. Effects of rhaponticin on

retinal oxidative stress andinflammation in diabetes throughNRF2/HO-1/NF-kB signaling.

Journal ofBiochemical and MolecularToxicology. 2020; e22568. (IF=3.642)

6. Yang M, Zhang YJ, Ma YN, Yan XJ, Gong LY, Zhang MZ* and Zhang BJ*. Nanoparticle-

based therapeutics of inflammatorybowel diseases: thecurrent state and prospects. Journal of

Bio-XResearch (2020) 3(4):157–173.

7. Liu C*, Zhang F, Hu J and Zhang MZ. A mini review on pH-sensitive photoluminescence in

carbon nanodots. Frontiers in Chemistry. 2020; 8: 1242. (IF=5.221)

8. XuJingwen*,Yan Xiangji, Ge Xin,ZhangMZ, Dang Xugang,Yang Yan, Xu Feng*,Luo

Yanling and GuoLiang Li. Novel multi-stimuli responsive functionalized PEG-based co-

delivery nanovehiclestoward sustainable treatments of multidrug resistant tumor. Journalof

Materials Chemistry B.2021;9, 1297-1314. (IF=6.331)

2019 年

1. Zhang MZ*, Yang CH, Yan XJ, Sung JK, Garg P and Merlin D. Highly Biocompatible

FunctionalizedLayer-by-Layer Ginger Lipid Nano Vectors Targeting P-Selectin for Delivery

ofDoxorubicin toTreat ColonCancer. AdvancedTherapeutics. 2019; 2:1900129. (Wiley new

journal)

2. Yang M, Zhang F, Yang C,Wang L, Sung J, Garg P, Zhang MZ* and Merlin, D. Oral targeted

delivery by nanoparticles enhances efficacy of an Hsp90 inhibitor by reducing systemic

exposure in murine models ofcolitis andcolitis-associatedcancer. Journal of Crohn'sand

Colitis. 2020; 14(1):130-141. (IF=9.071)

3. Wang X, Zhang MZ, Flores SR, Woloshun RR, Yang C, Yin L, Xiang P, Xu X, Garrick MD,

Vidyasagar S, Merlin D andCollinsJF*. Oral Gavageof GingerNanoparticle-Derived Lipid

VectorsCarrying Dmt1 siRNA Blunts Iron Loadingin MurineHereditary Hemochromatosis.

Molecular Therapy. 2019; 27(3):493-506.(IF=11.454)

4. Li C, Yang XQ, Zhang MZ, Song YY, Cheng K, An J, Zhang XS, Xuan Y, Liu B, Zhao YD.

In vivoImaging-Guided Nanoplatform for Tumor Targeting Deliveryand Combined Chemo-,

Gene-andPhotothermalTherapy. Theranostics. 2018; 8(20):5662. (IF=11.556)

5. Yang C, Zhang MZ, Sung J, Wang L, Jung Y and Merlin D. Autologous Exosome Transfer: A

New PersonalizedTreatment Concept to Prevent Colitisin a MurineModel. Journal ofCrohn's

and Colitis. 2019. (IF=9.071)

2018 年之前

1. Zhang MZ*, Xu CL, Wen LQ, Han MK, Xiao B, Zhou J and Merlin D. A hyaluronidase

responsive nanoparticle-based drug delivery system for targetingcolon cancercells.Cancer

Research.2016; 76(24),7208-7218. (IF=12.701)

2. Zhang MZ*, Viennois E, Prasad M, Zhang YC, Wang LX, Zhang Z and Merlin D. Edible

ginger-derived nanoparticles: a novel therapeuticapproachfor the prevention and treatment of

inflammatory bowel diseaseand colitis-associatedcancer. Biomaterials. 2016; 101:321-340.

(IF=12.479)

3. Zhang MZ, Yu Y, Yu RN, Wan M, Zhang RY and Zhao YD*. Tracking the down-regulation of

folate receptor-α incancer cells through target specific delivery of quantum dots coupled with

antisense oligonucleotide andtargeted peptide. Small. 2013; 9:4183-4193. (IF=13.281)

4. Zhang MZ*, Xiao B, Wang H, Han MK, Zhang Z, Viennois E and Merlin D. Edible ginger-

derived nano-lipids loaded withdoxorubicin asa novel drug-delivery approachfor colon

cancer therapy. Molecular Therapy. 2016; 24(10):1783-96. (IF= 11.454)

5. Zhang MZ*, Xu CL, Liu DD, Han MK, Wang LX and Merlin D. Oral delivery ofnanoparticles

loaded with ginger activecompound,6-shogaol, attenuates ulcerative colitisandpromotes

woundhealingina murine model of ulcerative colitis.Journalof Crohn’s and Colitis. 2018;

12(2):217-229. (IF=9.071)

6. Zhang MZ*, Viennois E, Xu CL and Merlin D. Plant derived edible nanoparticles as a new

therapeutic approach against diseases.Tissue Barriers. 2016; e1134415.

7. Zhang MZ*, Collins JF and Merlin D. Do Ginger-derived nanoparticles present an attractive

treatment strategy for inflammatory bowel disease? Nanomedicine. 2016; 3035-3037.

(IF=5.307)

8. Zhang MZ*, Wang XY, Han MK, Collins JF and Merlin D. Oral administration of ginger-

derivednano-lipidsloadedwithsiRNA as a novel approachforefficientsiRNA drug delivery

totreat ulcerative colitis. Nanomedicine. 2017; 12(16), 1927-1943. (IF=5.307)

9. Zhang MZ, Yu RN, Chen J, Ma ZY and Zhao YD*. Targeted quantum dots fluorescence

probes functionalized with aptamer and peptide for transferrin receptor on tumor cells.

Nanotechnology. 2012;23:485104. (IF=3.874)

10. Zhang MZ, Li C, Fang BY, Yao MH, Ren QQ, Zhang L and Zhao YD*. High transfection

efficiency of quantum dot-antisense oligonucleotide nanoparticles incancer cells through dual-

receptor synergistic targeting.Nanotechnology. 2014;25:255102. (IF=3.874)

11. Zhang MZ* and Merlin D. Nanoparticle-Based Oral Drug Delivery Systems Targeting the

Colon for Treatment ofUlcerative Colitis. Inflammatory Bowel Diseases. 2018; 24(7):1401-

1415. (IF=5.325)

12. Wen L, Jiang K, Zheng Y, Zhang MZ, Kondengaden SM, Li S, Wang GP*. Two-step chemoenzymatic detectingN-Acetylneuraminic acid-α (2-3)-galactose glycans. Journal of the American Chemical Society. 2016;138 (36):11473–11476. (Impact factor: 13.858)

13. Xiao B*, Zhang Z, Viennois E, Kang YJ, Zhang MZ, Han MK, et al. Combination therapy forulcerative colitis: orally targeted nanoparticles prevent mucosal damage and relieveinflammation. Theranostics. 2016;6(12):2250-2266. (Impactfactor: 8.712)

14. Xiao B*, Zhang MZ, Viennois E, Zhang Y, Wei N, Baker MT, et al. InhibitionofMDR1 gene expression and enhancing cellular uptake for effectivecolon cancer treatment using dual- surface-functionalized nanoparticles. Biomaterials. 2015;48:147-160. (Impactfactor: 8.402)

15. Xiao B*, Han MK, Viennois E, Wang L, Zhang MZ, Si X, et al. Hyaluronic acid- functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy. Nanoscale. 2015;7:17745-17755. (Impact factor: 7.367)

16. Yang J, Yao MH, Wen L, Song JT, Zhang MZ, Zhao YD*, Liu B*. Multifunctional quantum dot–polypeptide hybrid nanogel for targeted imaging and drug delivery. Nanoscale. 2014;6:11282-11292. (Impact factor: 7.367)

17. Zhou ZM, Zhou J, Chen J, Yu RN, Zhang MZ, Song JT, Zhao YD*. Carcino-embryonic antigen detectionbased on fluorescence resonance energy transfer between quantum dots and graphene oxide. Biosensors ＆ Bioelectronics. 2014;59:397-403. (Impact factor: 7.78)

18. Viennois E*, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang MZ, et al. Criticalrole ofPepT1 in promotingcolitis-associated cancer and therapeutic benefits of theanti-inflammatory

PepT1-mediated tripeptide KPV in a murine model. Cellular and Molecular Gastroenterology and Hepatology. 2016; 2:340-357. (Newjournal)

19. Xiao B*, Si X, Han MK, Viennois E, Zhang MZ, Merlin D. Co-delivery ofcamptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combinationchemotherapy. Journal ofMaterials Chemistry B. 2015;3:7724-7733. (Impact factor:4.543)

20. Xia HX, Yang XQ, Song JT, Chen J, Zhang MZ, Yan DM, Zhao YD*. Folic acid-conjugated silica-coated gold nanorods and quantum dots for dual-modality CT and fluorescence imaging and photothermal therapy.Journal of Materials Chemistry B.2014;2:1945-1953. (Impactfactor: 4.543)

21. Guan LY, Li YQ, Lin S, Zhang MZ, Chen J, Ma ZY, Zhao YD*. Characterization of CdTe/CdSe quantum dots-transferrin fluorescent probes for cellular labeling. Anal Chim Acta. 2012;741:86-92. (Impact factor: 4.95)

22. Xiao B*, Si X, Zhang MZ, Merlin D. Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy. Colloids and Surfaces B: Biointerfaces. 2015;135:379-385. (Impact factor: 3.887)

23. Zhang HL, Li YQ, Zhang MZ, Zhao YD*. Real-time observation of the effect of iron on receptor-mediated endocytosis of transferrin conjugated with quantum dots. Journal of Biomedical Optics. 2010;15:045003-045006. (Impact factor: 2.53)

24. Huang HH, Chen J, Meng YZ, Yang XQ, Zhang MZ, Yu Y, Zhao YD*. Synthesis and characterization of Bi2S3 composite nanoparticles with high X-ray absorption. Materials Research Bulletin. 2013;48:3800-3804. (Impact factor: 2.446)

25. Zhang HL#, Zhang MZ#, Li XY, Wan M, Li YQ, Zhang RY, Zhao YD*. A convenient method of preparinggene vector for real time monitoring transfection process based on the quantum dots. Materials Research Bulletin. 2012;47:3330-3335. (Impact factor: 2.446)

26. Wen W, Bao T, Yang J, Zhang MZ, Chen W, Xiong HY, Zhao YD*. A novel amperometricadenosine triphosphate biosensor by immobilizing graphene/dual-labeled aptamers complex onto poly (o-phenylenediamine) modified electrode. Sensors and Actuators B:Chemical. 2014;191:695-702. (Impact factor: 5.401)

27. Yu Y, Zhang MZ, Chen J, Zhao YD*. Homogeneous synthesis ofSiO2@TiO2 nanocomposites with controllable shell thickness and their enhanced photocatalytic activity. Dalton Transactions. 2013;42:885-889. (Impact factor: 4.029)

28. Zhou ZM, Yu Y, Zhang MZ, Chen J, Ren QQ, Song JT, Zhao YD*. Chemiluminescencedetection of lead (II) using ‘8–17’ DNAzyme and hemin/G-quadruplex with high sensitivity and selectivity. Sensors and Actuators B: Chemical. 2014;201:496-502. (Impact factor:5.401)

29. Xiao B*,Xu ZG, Viennois E, Zhang YC, Zhang Z, Zhang MZ, Han MK, Kang YJ, Merlin D. Orally Targeted DeliveryofTripeptide KPV via Hyaluronic Acid-functionalized Nanoparticles

Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. 2016; 25(7):1628-40. (Impact factor: 6.688)

30. Yang CH*, Zhang MZ, Merlin D. Advances in Plant-derived Edible Nanoparticles-based lipid Nano-drug Delivery Systems as Therapeutic Nanomedicines. Journal of Materials Chemistry B. 2018; 6:1312-1321. (Impact factor: 4.543)

31. Sung J, Yang C, Viennois E, Zhang MZ, Merlin D. Isolation, Purification, and Characterization ofGinger-derived Nanoparticles (GDNPs) from Ginger, Rhizome ofZingiber officinale. Bio Protoc. 2019;9(19):e3390.

32. Han MK, Baker M, Zhang Y, Yang C, Zhang MZ, Garg P, Viennois E, Merlin D.

Overexpression of CD98 in intestinalepithelium dysregulates miRNAsandtheirtargeted

proteins along the ileal villus-crypt axis. Scientific reports. 2018;8(1):1-16.

33. Viennois E*, Zhao Y, Han MK, Xiao B, Zhang MZ, Prasad M, Wang L, Merlin D. Serum miRNA signature diagnoses and discriminates murine colitis subtypesand predicts ulcerative colitis in humans.Scientific Reports. 2017;7:2520. (Impact factor: 4.259)

34. Zhang Y*, Viennois E, Zhang MZ, Xiao B, Han MK, Walter L, et al. PepT1 expression helps maintain intestinalhomeostasis by mediating the differential expression ofmiRNAs along the crypt-villus axis. Scientific Reports. 2016;6:27119.(Impact factor: 4.259)

35. Chen GW, Zhang MZ, Zhao LF, Xu CS*. Expression patterns and action analysis of genesassociated with physiological responses during rat liver regeneration: Innate immune response.

World Journal of Gastroenterology. 2006;12:7852-7858. (Impact factor: 3.365)

会议论文：

1. Zhang MZ*, Viennois E, Merlin D.Tu1876 Ginger derivednanoparticles: a novel therapeutic approach for the treatment ofIBD. Gastroenterology. 2016;150:S966. (Impact factor: 18.392)

2. Zhang MZ*, Viennois E, Merlin D. P-139 YI Ginger derived nanoparticles: a novel therapeutic approach for the treatment of IBD. Inflammatory Bowel Disease. 2016;22:S52-S53.(Impact factor: 4.525)

3. Xiao B*, Viennois E, Zhao Y, Zhang Y, Jung Y, ZhangMZ, et al. Mo1204 inhibition ofMDR1 gene expression and enhancing cellular uptake for effective colon cancer treatmentusing dual-surface-functionalized nanoparticles. Gastroenterology. 2015;148:S638. (Impact factor: 18.392)

4. Viennois E*, Zhao Y, Zhang MZ, Han M, Merlin D. O-016 YI Longitudinal study of circulating miRNAbiomarkers in inflammatory bowel disease. Inflammatory Bowel Diseases. 2016;22:S6. (Impact factor: 4.525)

5. Zhang MZ*, Didier Merlin.Curcuma Longa-derived nanoparticles reduce colitisandpromote intestinal wound repair by inactivating the NF-file:///C:/Users/yzl05/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gifB pathway. Gastroenterology. 2017;152(5):S567. (Impact factor: 18.392)

6. Zhang MZ*, Yang CH and Didier Merlin. P084 Oral delivery of nanoparticles loaded withginger active compound, 6-shogaol, attenuates ulcerative colitis and promoteswound healingin a murine model of ulcerative colitis. Gastroenterology. 2018; 154(1):S44. (Impact factor: 18.392)

团队成员：

张明真（研究员/PI，毕业于华中科技大学）

刘翠（副教授，毕业于武汉大学）

方碧云（助理教授，毕业于华中科技大学）

张玉洁（助理教授，毕业于中国科学院大学生物物理研究所）

屈相龙（助理教授，毕业于同济大学）

杨梅（2018 级博士，毕业于西安交通大学）

颜湘冀（2019 级博士，毕业于西安交通大学）

马雅娜（2019 级博士，毕业于厦门大学）

高文慧（2019 级硕士，毕业于河南师范大学）

张媛媛（2020 级博士，毕业于北京大学）

贾真真（2021 级博士，西安交通大学硕博连读）